) latest earnings, investors are increasingly curious over the types of innovation biotech stocks could offer. But with so many names and new research coming out every day, it can be difficult to find where to start.citing continued growth in its core Vyvgart franchise — a drug that helps treat neuromuscular junction disease myasthenia gravis — and additional market opportunities involved with the franchise to help treat other ailments and conditions.
But it is a high cost drug and in demand for these people because they can be debilitating what they have.They're all orphan diseases, which is defined as under 250,000 patients in the United States. People's expectations are quite high for C ID P got you, as evidenced by what we've seen in the stocks this year to date.And like the other chart, this stock has seen a big slump over the past 12 months, although it has bounced back some year to date.The growth in the US hasn't existed for years.Ex US growth has been choppy and I think they're reaching saturation.
So I think they'll hit that in France, too, based on the numbers that they posted up recently and sort of in contrast with what we were just talking about in terms of expanded indications for other types of cancer, for example, is there any kind of opportunity there, So they have been approved to treat brain metastases caused by lung cancer?
Россия Последние новости, Россия Последние новости
Similar News:Вы также можете прочитать подобные новости, которые мы собрали из других источников новостей
Источник: YahooFinanceCA - 🏆 47. / 63 Прочитайте больше »
Источник: YahooFinanceCA - 🏆 47. / 63 Прочитайте больше »